PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026Cell Reports Medicine1 citationsOpen Access

Engineered oncolytic virus armed with anti-PCSK9 scFv boosts long-term CD8+ T cell immunity via rewiring MHC-I antigen presentation

HFHuolun FengYZYuhan ZhangZHZuda Huang

Key Points

  • This research aims to determine how an engineered oncolytic virus impacts CD8+ T cell immunity through MHC-I antigen presentation.
  • Developed an oncolytic virus armed with anti-PCSK9 scFv
  • Measured long-term CD8+ T cell responses
  • Analyzed changes in MHC-I antigen presentation
  • Significant increase in long-term CD8+ T cell immunity observed
  • Enhanced MHC-I antigen presentation correlated with improved immune responses

Abstract

Engineered oncolytic virus armed with anti-PCSK9 scFv boosts long-term CD8 + T cell immunity via

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Feng et al. (2026) studied this question.

synapsesocial.com/papers/69cf5d775a333a821460b3cahttps://doi.org/10.1016/j.xcrm.2026.102724
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhanced cellular therapy: revolutionizing adoptive cellular therapy2024 · 22 citations
  2. 2Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes2020 · 74 citations
  3. 3Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer2025 · 7 citations
  4. 4Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside2020 · 212 citations
  5. 5Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency2014 · 140 citations